Literature DB >> 29954755

High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility.

Laura Z Vanags1,2, Nathan K P Wong1,2,3, Stephen J Nicholls3,4, Christina A Bursill1,3,4.   

Abstract

Revascularization because of coronary artery disease is commonly achieved by percutaneous coronary intervention with stent deployment. Refinement in interventional techniques, major improvements in stent design (particularly drug-eluting stents), and adjunctive pharmacotherapy with dual antiplatelet regimens have led to marked reductions in the overall rates of stent failure. However, even with the advancements made in the latest generation of drug-eluting stents, unresolved biological problems persist including delayed re-endothelialization and neoatherosclerosis, which can promote late expansion of the neointima and late stent thrombosis. Novel strategies are still needed beyond what is currently available to specifically address the pathobiological processes that underpin the residual risk for adverse clinical events. This review focuses on the emerging evidence that HDL (high-density lipoproteins) and its main apo (apolipoprotein), apoA-I, exhibit multiple vascular biological functions that are associated with an improvement in stent biocompatibility. HDL/apoA-I have recently been shown to inhibit in-stent restenosis in animal models of stenting and suppress smooth muscle cell proliferation in in vitro studies. Reconstituted HDL also promotes endothelial cell migration, endothelial progenitor cell mobilization, and re-endothelialization. Furthermore, reconstituted HDL decreases platelet activation and HDL cholesterol is inversely associated with the risk of thrombosis. Finally, reconstituted HDL/apoA-I suppresses key inflammatory mechanisms that initiate in-stent neoatherosclerosis and can efflux cholesterol from plaque macrophages, an important function of HDLs that prevents plaque progression. These unique multifunctional effects of HDL/apoA-I suggest that, if translated appropriately, have the potential to improve stent biocompatibility. This may provide an alternate and more efficacious therapeutic pathway for the translation of HDL.

Entities:  

Keywords:  apolipoprotein A-I; coronary artery disease; hyperplasia; stents; thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29954755     DOI: 10.1161/ATVBAHA.118.310788

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  Salinomycin-Loaded High-Density Lipoprotein Exerts Promising Anti-Ovarian Cancer Effects by Inhibiting Epithelial-Mesenchymal Transition.

Authors:  Miao Zou; Xirui Yin; Xuan Zhou; Xinhui Niu; Yi Wang; Manman Su
Journal:  Int J Nanomedicine       Date:  2022-09-08

Review 2.  High-density lipoprotein-mediated cardioprotection in heart failure.

Authors:  Ampadu O Jackson; Jun Meng; Huifang Tang; Kai Yin
Journal:  Heart Fail Rev       Date:  2021-07       Impact factor: 4.214

3.  CXCR4-Binding Positron Emission Tomography Tracers Link Monocyte Recruitment and Endothelial Injury in Murine Atherosclerosis.

Authors:  Osamu Baba; Li-Hao Huang; Andrew Elvington; Martyna Szpakowska; Deborah Sultan; Gyu Seong Heo; Xiaohui Zhang; Hannah Luehmann; Lisa Detering; Andy Chevigne; Yongjian Liu; Gwendalyn J Randolph
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-17       Impact factor: 8.311

4.  Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles.

Authors:  Yuzhou Xue; Jian Shen; Weifeng Hong; Wei Zhou; Zhenxian Xiang; Yuansong Zhu; Chuiguo Huang; Suxin Luo
Journal:  Lipids Health Dis       Date:  2021-05-06       Impact factor: 3.876

5.  Impaired Cholesterol-Uptake Capacity of HDL Might Promote Target-Lesion Revascularization by Inducing Neoatherosclerosis After Stent Implantation.

Authors:  Yuichiro Nagano; Hiromasa Otake; Takayoshi Toba; Koji Kuroda; Yuto Shinkura; Natsuko Tahara; Yoshiro Tsukiyama; Kenichi Yanaka; Hiroyuki Yamamoto; Akira Nagasawa; Hiroyuki Onishi; Yoichiro Sugizaki; Ryo Takeshige; Amane Harada; Katsuhiro Murakami; Maria Kiriyama; Toshihiko Oshita; Yasuhiro Irino; Hiroyuki Kawamori; Tatsuro Ishida; Ryuji Toh; Toshiro Shinke; Ken-Ichi Hirata
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

6.  Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.

Authors:  Bahman Hooshdaran; Benjamin B Pressly; Ivan S Alferiev; Jonathan D Smith; Philip W Zoltick; Cory M Tschabrunn; Robert L Wilensky; Robert C Gorman; Robert J Levy; Ilia Fishbein
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.996

Review 7.  Advances in HDL: Much More than Lipid Transporters.

Authors:  Soumaya Ben-Aicha; Lina Badimon; Gemma Vilahur
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

8.  The Early Predictive Value of Circulating Monocytes and Eosinophils in Coronary DES Restenosis.

Authors:  Shumei Li; Hong Qiu; Zhaorong Lin; Lin Fan; Yongzhe Guo; Yujie Zhang; Lianglong Chen
Journal:  Front Cardiovasc Med       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.